Skip to main content

Table 2 Prevalence of Cervical, Vulvar, Anal and Oral Human papillomavirus infections among sexually active women from the general population in two communities in Ibadan, Nigeria (N = 310)

From: Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women

Variable Cervical sample Vulvar sample Anal sample Oral sample
n/N1 Prevalence % [95% CI] n/N Prevalence (%) [95% CI] n/N Prevalence (%) [95% CI] n/N Prevalence (%) [95% CI]
Any HPV genotype   p = 0.014*   p = 0.523   p = 0.021*   p = 0.669
 18–24 years 79/118 66.9 (57.8–75.3) 86/121 71.1 (62.1–79.0) 74/120 61.7 (52.4–70.4) 20/111 18.0 (11.4–26.4)
 25–34 years 62/100 62.0 (51.7–71.5) 68/100 68.0 (57.9–77.0) 57/97 58.9 (48.3–68.7) 15/92 16.3 (9.4–25.5)
 35–45 years 41/87 47.1 (36.3–58.1) 56/88 63.6 (52.7–73.6) 41/86 47.7 (36.8–58.7) 11/83 13.3 (6.8–22.5)
 Overall 182/305 59.7 (53.9–65.2) 210/309 68.0 (62.4–73.1) 172/303 56.8 (51.0–62.4) 46/286 16.1 (12.0–20.9)
HPV classification by IARC2 Class 1—Carcinogenic3   p = 0.074*   p = 0.026*   p = 0.230*   p = 0.967
 18–24 years 58/118 49.2 (39.8–58.5) 65/121 53.7 (44.4–62.8) 50/120 41.7 (32.7–51.0) 11/111 9.9 (5.1–17.0)
 25–34 years 41/100 41.0 (31.3–51.3) 48/100 48.0 (37.9–58.2) 38/97 39.2 (29.4–49.6) 9/92 9.9 (4.6–17.8)
 35–45 years 29/87 33.3 (23.6–44.3) 36/88 40.9 (30.5–51.9) 26/86 30.2 (20.8–41.1) 9/83 10.8 (5.1–19.6)
 Overall 128/305 42.0 (36.4–47.7) 149/309 48.2 (42.5–53.9) 114/303 37.6 (32.1–43.3) 29/286 10.1 (6.9–14.2)
Class 2A—Probable carcinogenic4   p = 0.8355   p = 0.954   p = 0.094b   p = 0.749b
 18–24 years 5/118 4.2 (1.4–9.6) 9/121 7.4 (3.5–13.7) 8/120 6.7 (2.9–12.7) 1/111 0.9 (0.02–4.9)
 25–34 years 4/100 4.0 (1.1–9.9) 8/100 8.0 (3.5–15.2) 1/97 1.0 (0.0–5.6) 0/92 0
 35–45 years 5/87 5.7 (1.9–12.9) 6/88 6.8 (2.5–14.3) 5/86 5.8 (1.9–13.0) 1/83 1.2 (0.03–6.5)
 Overall 14/305 4.6 (2.5–7.6) 23/309 7.4 (4.8–11.0) 14/303 4.6 (2.5–7.6) 2/286 0.7 (0.08–2.5)
Class 2B—Possible carcinogenic6   p = 0.006*   p = 0.102   p = 0.265   p = 0.966
 18–24 years 54/118 45.8 (36.6–55.2) 60/121 49.6 (40.4–58.8) 47/120 39.2 (30.4–48.5) 7/111 6.3 (2.6–12.6)
 25–34 years 40/100 40.0 (30.3–50.3) 50/100 50.0 (39.8–60.2) 40/97 41.2 (31.3–51.7) 6/92 6.5 (2.4–13.7)
 35–45 years 21/87 24.1 (15.6–34.5) 32/88 36.4 (26.4–47.3) 26/86 30.2 (20.8–41.1) 6/83 7.2 (2.7–15.1)
 Overall 115/305 37.7 (32.2–43.4) 142/309 46.0 (40.3–51.7) 113/303 37.3 (31.8–43.0) 19/286 6.6 (4.0–10.2)
Class 3—Unclassified7   p = 0.019*   p = 0.154   p = 0.597   p = 0.835
 18–24 years 14/118 11.9 (6.6–19.1) 16/121 13.2 (7.8–20.6) 12/120 10.0 (5.3–16.8) 4/111 3.6 (0.9–9.0)
 25–34 years 5/100 5.0 (1.6–11.3) 8/100 8.0 (3.5–15.2) 6/97 6.2 (2.3–13.0) 2/92 2.2 (0.3–7.6)
 35–45 years 2/87 2.3 (0.3–8.1) 5/88 5.7 (1.9–12.8) 7/86 8.1 (3.3–16.1) 3/83 3.6 (0.8–10.2)
 Overall 21/305 6.9 (4.3–10.3) 29/309 9.4 (6.4–13.2) 25/303 8.3 (5.4–11.9) 9/286 3.1 (1.4–5.9)
Any HR-HPV genotypes8   p = 0.095*   p = 0.142*   p = 0.243   p = 0.965
 18–24 years 60/118 53.1 (44.7–61.3) 69/121 59.3 (51.0–67.3) 53/120 44.2 (35.1–53.5) 12/111 10.8 (5.7–18.1)
 25–34 years 44/100 38.0 (28.1–48.8) 51/100 44.6 (34.2–55.3) 38/97 39.2 (29.4–49.6) 9/92 9.8 (4.6–17.8)
 36–45 years 31/87 33.3 (22.2–46.0) 38/67 41.8 (29.8–54.5) 28/86 32.6 (22.8–43.5) 9/83 10.8 (5.1–19.6)
 Overall 135/305 44.3 (38.6–50.0) 158/309 51.1 (45.4–56.8) 119/303 39.3 (33.7–45.0) 30/286 10.5 (7.2–14.6)
Any LR-HPV genotype9   p = 0.001*   p = 0.047*   p = 0.495   p = 0.891
 18–24 years 60/118 50.8 (41.5–60.2) 66/121 54.5 (45.2–63.6) 56/120 46.7 (37.5–56.0) 11/111 9.9 (5.1–17.0)
 25–34 years 41/100 41.0 (31.3–51.3) 50/100 50.0 (39.8–60.2) 44/97 45.4 (35.2–55.8) 8/92 8.7 (3.8–16.4)
 35–45 years 22/87 25.3 (16.6–35.7) 33/88 37.5 (27.4–48.5) 33/86 38.4 (28.1–49.5) 9/83 10.8 (5.1–19.6)
 Overall 123/305 40.3 (34.8–46.1) 149/309 48.2 (42.5–53.9) 133/303 43.9 (38.2–49.7) 28/286 9.8 (6.6–13.8)
Multiple HPV genotypes infection10   p < 0.001*   p = 0.012*   p = 0.014*   p = 0.7215
 18–24 years 54/118 45.8 (36.6–55.2) 59/121 48.7 (39.6–58.0) 51/120 42.5 (33.5–51.9) 4/111 3.6 (1.0–9.0)
 25–34 years 29/100 29.0 (20.4–38.9) 42/100 42.0 (32.2–52.3) 31/97 32.0 (22.9–42.2) 4/92 4.3 (1.2–10.8)
 35–45 years 18/87 20.7 (12.7–30.7) 25/88 28.4 (19.3–39.0) 20/86 23.3 (14.8–33.6) 5/83 6.0 (2.0–13.5)
 Overall 101/305 33.1 (27.9–38.7) 126/309 40.8 (35.2–46.5) 102/303 33.7 (28.4–39.3) 13/286 4.5 (2.4–7.6)
  1. 1n/N—number of samples with positive HPV infection as numerator and total samples with valid result as denominator; 2IARC—International Agency for Research on Cancer (*HPV genotypes in IARC classification that are not included in the Anyplex II HPV28 platform); 3Class 1 IARC HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; 4Class 2A IARC HPV—68; 5Bartlett’s test for equal variances were significant (p < 0.05); 6Class 2B IARC HPV—5*, 8*, 26, 30*, 34*, 40, 42, 43, 44, 53, 54, 55*, 61, 66, 67*, 69, 70, 71*, 72*, 73, 81*, 82, 83*, 84*, 85*, 97*, IS39* and CP6108*; 7Class 3 IARC HPV—6, 11; 8HR-HPV Group—Class 1 IARC HPV and Class 2A IARC HPV; 9LR-HPV—Class 2b IARC and Class 3 IARC; 10Multiple HPV infection-detection of two or more genotypes of HPV by Anyplex II HPV28 from a sample. All invalid samples were excluded from the descriptive analysis